Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

John M. Baer

Matched on ORCID iD 0000-0002-8758-0030; NIH RePORTER profile ID 15167841. Sources: OpenAlex.

Their work

Papers
9 (first author 3, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
34
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper, 1 grant · 2023: 4 papers · 2024: 1 paper · 2025: 1 paper

Papers 9

  1. Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1821↗
  2. Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-23-0428↗
  3. Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology. Co-author DOI 10.1007/s00262-023-03463-x↗
  4. Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC. Co-author DOI 10.1038/s41590-023-01579-x↗
  5. Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunotherapy. First author DOI 10.1084/jem.20212062↗
  6. Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. First author DOI 10.1158/2326-6066.cir-21-0946↗
  7. Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer. Co-author DOI 10.1038/s41588-022-01157-1↗
  8. Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2020.02.008↗
  9. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. First author DOI 10.1038/s41467-018-03600-6↗

Grants 1

  1. Investigating the relationship between macrophage ontogeny and function during pancreatitis F31DK122633↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David G DeNardo · 8 shared papers, 2018–2025 · strength 1.09
  2. Ryan C Fields · 6 shared papers, 2018–2024 · strength 0.76
  3. William G. Hawkins · 5 shared papers, 2018–2023 · strength 0.59
  4. Varintra E. Lander · 4 shared papers, 2020–2024 · strength 0.55
  5. Kian‐Huat Lim · 3 shared papers, 2023–2025 · strength 0.47
  6. Liang‐I Kang · 3 shared papers, 2023–2024 · strength 0.47
  7. Li Ding · 3 shared papers, 2023–2024 · strength 0.45
  8. C. Alston James · 3 shared papers, 2023 · strength 0.43
  9. Graham D. Hogg · 3 shared papers, 2020–2023 · strength 0.38
  10. Chong Zuo · 3 shared papers, 2020–2023 · strength 0.37
  11. Jad I. Belle · 2 shared papers, 2023–2024 · strength 0.31
  12. Usman Younis Panni · 2 shared papers, 2023 · strength 0.29
  13. Patrick M. Grierson · 1 shared paper, 2025 · strength 0.19
  14. Katrina Sophia Pedersen · 1 shared paper, 2025 · strength 0.19
  15. Andrea Wang‐Gillam · 1 shared paper, 2025 · strength 0.19
  16. Blake E. Sells · 1 shared paper, 2024 · strength 0.17
  17. Paolo Provenzano · 1 shared paper, 2024 · strength 0.17
  18. Guhan Qian · 1 shared paper, 2024 · strength 0.17
  19. Hyun Jee Kim · 1 shared paper, 2024 · strength 0.17
  20. Feng Gao · 1 shared paper, 2023 · strength 0.14
  21. Yu Zhu · 1 shared paper, 2023 · strength 0.14
  22. Daoxiang Zhang · 1 shared paper, 2023 · strength 0.14
  23. William E. Gillanders · 1 shared paper, 2023 · strength 0.14
  24. Paarth B. Dodhiawala · 1 shared paper, 2023 · strength 0.14
  25. Daniel Cui Zhou · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.